Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...

Many professionals report awareness, but few actively prescribe the self-administered injectable contraceptive DMPA.

The collaboration between ten23 health and BD aims to commercialize the BD Libertas wearable injector for large-volume ...